&nbsp;

view-print-pcir-01.png

Dec 1969

Document

view-print-pcir-02.png

Dec 1969

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2023

Status: Current
Version: PET 2023-2

Dec 1969

Document

EmotionalandPsychologicalWell-beingforGyngecologicalCancerSurvivors.pdf

Jul 2024

Document

Emotional-and-Psychological-Well-being-Gynecological_FR.pdf

Jul 2024

Document

Vaginal-Vault-Testing-FAQs.pdf

Dec 1969

Regimen

ENHE

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

Enhertu trastuzumab deruxtecan (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

ENFO+PEMB

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

enfortumab vedotin (Compassionate),

pembrolizumab (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

ENHE

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Drugs Used:

Enhertu trastuzumab deruxtecan (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

ELRA; ELRA(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

elranatamab (Compassionate)

Quick Link(s):

Regimen Monograph

Drug

enfortumab vedotin

Other Name(s): Padcev®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jan 2025

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin